Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
27.6M
-
Shares change
-
+9.69M
-
Total reported value, excl. options
-
$50.2M
-
Value change
-
+$17.7M
-
Put/Call ratio
-
1.3
-
Number of buys
-
19
-
Number of sells
-
-17
-
Price
-
$1.82
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q2 2024
57 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q2 2024.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.6M shares
of 67.8M outstanding shares and own 40.72% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (6.94M shares), SAMLYN CAPITAL, LLC (6.12M shares), Point72 Asset Management, L.P. (5.96M shares), ADAMS STREET PARTNERS LLC (3.28M shares), VANGUARD GROUP INC (1.65M shares), RENAISSANCE TECHNOLOGIES LLC (564K shares), BlackRock Inc. (562K shares), GEODE CAPITAL MANAGEMENT, LLC (460K shares), TOWERVIEW LLC (400K shares), and MORGAN STANLEY (371K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.